York GP Ltd. decreased its holdings in Danaher Co. (NYSE:DHR - Free Report) by 75.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,000 shares of the conglomerate's stock after selling 15,000 shares during the period. Danaher comprises about 0.8% of York GP Ltd.'s investment portfolio, making the stock its 2nd biggest holding. York GP Ltd.'s holdings in Danaher were worth $1,025,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of DHR. Norges Bank bought a new stake in shares of Danaher in the fourth quarter worth $2,130,740,000. GAMMA Investing LLC grew its holdings in shares of Danaher by 24,958.2% in the first quarter. GAMMA Investing LLC now owns 1,870,847 shares of the conglomerate's stock worth $383,524,000 after acquiring an additional 1,863,381 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Danaher in the fourth quarter worth $391,172,000. Two Sigma Advisers LP grew its holdings in shares of Danaher by 4,248.8% in the fourth quarter. Two Sigma Advisers LP now owns 1,639,500 shares of the conglomerate's stock worth $376,347,000 after acquiring an additional 1,601,800 shares during the period. Finally, Capital World Investors grew its holdings in Danaher by 32.7% during the fourth quarter. Capital World Investors now owns 6,361,183 shares of the conglomerate's stock valued at $1,460,215,000 after purchasing an additional 1,566,658 shares during the period. Institutional investors own 79.05% of the company's stock.
Insider Buying and Selling
In related news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the sale, the chairman now directly owns 3,105,808 shares in the company, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Christopher Paul Riley sold 15,805 shares of the company's stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the sale, the executive vice president now owns 15,179 shares in the company, valued at approximately $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.10% of the stock is owned by company insiders.
Danaher Price Performance
NYSE:DHR opened at $200.51 on Monday. The company has a current ratio of 1.40, a quick ratio of 1.05 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $143.50 billion, a P/E ratio of 37.98, a P/E/G ratio of 2.66 and a beta of 0.77. Danaher Co. has a 12 month low of $171.00 and a 12 month high of $281.70. The business's 50-day moving average is $192.80 and its 200 day moving average is $210.81.
Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. The company had revenue of $5.74 billion for the quarter, compared to the consensus estimate of $5.58 billion. Danaher had a return on equity of 10.82% and a net margin of 16.33%. On average, equities research analysts forecast that Danaher Co. will post 7.63 earnings per share for the current fiscal year.
Danaher Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. Danaher's dividend payout ratio is currently 24.85%.
Analyst Upgrades and Downgrades
DHR has been the subject of several recent research reports. TD Cowen boosted their price target on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a report on Wednesday, April 23rd. Stifel Nicolaus raised Danaher from a "hold" rating to a "buy" rating and set a $260.00 price target for the company in a report on Friday, March 14th. Guggenheim reissued a "buy" rating and set a $250.00 price target on shares of Danaher in a report on Wednesday, April 23rd. Deutsche Bank Aktiengesellschaft cut their price target on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Finally, Robert W. Baird cut their price target on Danaher from $231.00 to $225.00 and set an "outperform" rating for the company in a report on Wednesday, April 23rd. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $248.17.
View Our Latest Stock Analysis on DHR
Danaher Company Profile
(
Free Report)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
